Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals
oleh: Debora Stelitano, Stuart P. Weisberg, Monica P. Goldklang, Yun Zhu, Francesca T. Bovier, Gavreel F. Kalantarov, Giuseppe Greco, Didier Decimo, Gianluigi Franci, Michele Cennamo, Giuseppe Portella, Massimiliano Galdiero, Cyrille Mathieu, Branka Horvat, Ilya N. Trakht, Anne Moscona, Michael A. Whitt, Matteo Porotto
| Format: | Article |
|---|---|
| Diterbitkan: | American Society for Microbiology 2021-08-01 |
Deskripsi
Assays for rapid biosafety level 2 (BSL2) evaluation of neutralizing properties of antibodies acquired via natural infection or through vaccination is urgently needed. Here, we propose a combinatorial approach in which sera are screened for SARS-CoV-2 spike protein (S) binding using a cell-based immunofluorescent (CBI) assay, and positive samples are further evaluated in a pseudotyped viral multicycle infection-mimicking protocol under BSL2 conditions.